NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform

Nevro (NVRO) recently announced the FDA clearance and limited market release of HFX iQ with HFX AdaptivAI, a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system. HFX AdaptivAI uses artificial intelligence (AI) to provide responsive, individualized pain treatment in real-time by combining insights from over 100,000 patients and over 100 million data points. Likely Trend of NVRO Stock Following the News Following the announcement, shares of the company cl ...